A recent clinical trial demonstrates that psilocybin rapidly reduces depression symptoms within days, highlighting its potential as a fast-acting intervention for depressive disorders.
The Department of Veterans Affairs has initiated a clinical trial evaluating MDMA-assisted therapy for veterans with mental health conditions, representing a significant step in the development of novel psychopharmacological treatments for PTSD and related disorders.
A decentralized Phase 4 trial evaluates the efficacy and safety of viloxazine ER in adults with ADHD and comorbid depression or anxiety, leveraging its multimodal norepinephrine and serotonin profile.
A clinical trial at Hasanuddin University evaluates the efficacy of adding Cognitive Behavioral Therapy to risperidone for schizophrenia treatment.
A clinical trial is recruiting to evaluate psilocybin as a treatment for residual anhedonia and emotional blunting, addressing a key symptom of depression often resistant to standard pharmacotherapy.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 03 – May 27)
- Consider initiating long-acting injectable antipsychotics early in the schizophrenia treatment course to improve adherence and reduce relapse, rather than reserving them for established non-adherence.
- For alcohol withdrawal management, prefer lorazepam over diazepam in patients with hepatic impairment or when cost-effectiveness is a priority due to its safer metabolic profile.
- Utilize combination antidepressant therapy as a first-line strategy for acute severe depression or nonresponding cases, as evidence supports its superior efficacy over monotherapy.
- Apply ASCP consensus guidelines to structure the timing and methods of stimulant deprescribing in ADHD care to ensure safe and systematic management.
- Monitor for somnolence and gastrointestinal effects as the primary adverse events when prescribing pharmaceutical-grade CBD for developmental and epileptic encephalopathies.
- Evaluate viloxazine ER as a multimodal option for adults with ADHD comorbid with depression or anxiety, leveraging its norepinephrine and serotonin reuptake inhibition.
- Recognize that inpatient benzodiazepine care is primarily for stabilization rather than complete discontinuation, and anticipate insurance barriers that may complicate safe outpatient deprescribing.
- Assess the potential for psilocybin-assisted therapy to address residual anhedonia and emotional blunting in depression, symptoms often resistant to standard pharmacotherapy.
- Consider the emerging evidence for psilocybin's rapid antidepressant effects and sustained relief in treatment-resistant depression when counseling patients on novel interventions.
- Review the comparative efficacy and pharmacokinetics of benzodiazepines when managing alcohol withdrawal to tailor selection to individual patient safety and cost profiles.
Diagnosis & Treatment 3
This review advocates for initiating long-acting injectable antipsychotics early in the course of schizophrenia to improve adherence, reduce relapse, and optimize long-term outcomes, challenging the practice of reserving LAIs for patients with established non-adherence.
A study indicates that psilocybin therapy may provide sustained relief from depression for several months, highlighting the potential long-term efficacy of this psychedelic treatment.
Research investigating optimal dosing levels for ADHD medications provides clinical guidance for prescribing psychiatrists seeking to maximize efficacy and minimize side effects.
Drug Development 3
A study conducted at Sheppard Pratt suggests psilocybin-assisted therapy may reduce chronic suicidal ideation, highlighting a potential psychopharmacological intervention for high-risk psychiatric patients.
Alkermes is presenting new data on psychiatry and orexin biology at the ASCP annual meeting, indicating potential updates on its pipeline or mechanism of action relevant to psychopharmacology.
Optimi Health is advancing a 6% psilocybin extract for the treatment of treatment-resistant depression, representing an ongoing development in psychedelic pharmacotherapy.
Clinical Pearl 2
A clinical trial is recruiting patients taking specific antipsychotics (olanzapine, quetiapine, risperidone, clozapine) to evaluate the efficacy of a probiotic formula compared to placebo.
A nonrandomized open-label trial investigates the safety and tolerability of single-dose psilocybin for PTSD, contributing to the early-stage clinical evaluation of this psychedelic agent for a major psychiatric indication.
Mechanism of Action 4
Preclinical mouse data shows a single dose of psilocybin provides prolonged relief from nerve pain, suggesting potential mechanisms for pain management relevant to psychiatric pharmacology.
This pilot study identifies psilocybin-induced DNA methylation changes in genes related to neuroplasticity and immune function in patients with alcohol use disorder, offering mechanistic insights into its potential therapeutic effects despite failing to meet primary clinical endpoints.
Preclinical study in mice elucidates the relationship between psilocybin's behavioral effects, 5-HT2A receptor occupancy, and neuroplastic changes, providing mechanistic insight into its antidepressant potential.
This article discusses the mechanisms of psilocybin for treating PTSD, a topic within the scope of psychiatric pharmacology and novel therapeutic agents.
Substance Use 2
Multi-modal cannabis use is associated with a fourfold higher risk of Cannabis Use Disorder compared to oral-only use, highlighting the need to assess delivery methods in clinical evaluations.
A systematic review evaluates the impact of psychedelics on craving in substance use disorders, contributing to the evidence base for psychedelic-assisted therapy in addiction treatment.
Journal Article 3
A meta-analysis of 46 studies confirms pharmaceutical-grade CBD provides clinically meaningful seizure reduction in approximately half of patients with developmental and epileptic encephalopathies, with a manageable safety profile dominated by somnolence and GI effects.
A systematic review and network meta-analysis evaluates the efficacy of psychedelics for managing psychological and existential distress in terminally ill patients, providing evidence for their use in palliative care settings.
An updated systematic review and meta-analysis evaluates the efficacy of psilocybin for major depressive disorder, providing evidence on this psychedelic intervention for treatment-resistant depression.